Product Information

BUPRENORPHINE-NALOXONE 8-2 MG SL TABLET is a generic product labeled by Accord Healthcare Inc., priced at $0.7351 per EA under NDC 16729055010. Its NADAC has been published 301 times since Feb 17, 2021.

FDA first approved this application on Jul 17, 2020. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

BUPRENORPHINE-NALOXONE 8-2 MG SL TABLET

BUPRENORPHINE HYDROCHLORIDE and NALOXONE HYDROCHLORIDE DIHYDRATE
$0.7351per EA
DEA Schedule CIII

Strength

8; 2 mg/1; mg/1

NDC

16729055010

Classification

Generic

Dosage Form

TABLET

Route

SUBLINGUAL

Effective Date

11/18/2026

Approval Type

Generic (ANDA)

FDA Application

ANDA209069

FDA Approved

7/17/2020

TE Code

AB

On Market Since

9/1/2020

Pharmacological Classes

Opioid Antagonist
Opioid Antagonists
Partial Opioid Agonist
Partial Opioid Agonists

Price Statistics

The NADAC for BUPRENORPHINE-NALOXONE 8-2 MG SL TABLET has been published 301 times since Feb 17, 2021, and over the history we have for it it has declined 38.7%. The table below summarizes its recorded NADAC range and movement.

Current price$0.7351 per EA
All-time high$1.2290 (May 12, 2021)
All-time low$0.6322 (Jul 22, 2026)
52-week high$0.7351
52-week low$0.6322
Median price$0.9381
Average price$0.8977
Largest weekly change+29.6% (Aug 21, 2024)
Weeks tracked301
Tracking sinceFeb 17, 2021

Price History

1W

+2.5%

1M

+10.9%

3M

+15.2%

6M

+8.4%

1Y

+4.6%

3Y

-20.9%

5Y

-26.3%

All

-38.7%

Generic Alternatives

No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the BUPRENORPHINE HYDROCHLORIDE and NALOXONE HYDROCHLORIDE DIHYDRATE market page.

Lowest-Cost Alternatives

No alternatives available

No alternatives found with the same active ingredient and strength in a comparable dosage form.

Continue researching this drug

Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.

Frequently asked questions

What is the NADAC price of BUPRENORPHINE-NALOXONE 8-2 MG SL TABLET?

The current National Average Drug Acquisition Cost (NADAC) for BUPRENORPHINE-NALOXONE 8-2 MG SL TABLET, manufactured by Accord Healthcare Inc., is $0.7351 per EA (NDC 16729055010), effective Nov 18, 2026.

How has the price of BUPRENORPHINE-NALOXONE 8-2 MG SL TABLET changed over time?

Over the history we have for it, the NADAC for BUPRENORPHINE-NALOXONE 8-2 MG SL TABLET has declined 38.7%. It has been tracked across 301 weekly CMS publications since Feb 17, 2021.

What are the highest and lowest recorded NADAC prices for BUPRENORPHINE-NALOXONE 8-2 MG SL TABLET?

Since Feb 17, 2021, the NADAC for BUPRENORPHINE-NALOXONE 8-2 MG SL TABLET has ranged from a low of $0.6322 (Jul 22, 2026) to a high of $1.2290 (May 12, 2021), with a median of $0.9381 per EA.

Are there cheaper alternatives to BUPRENORPHINE-NALOXONE 8-2 MG SL TABLET?

No other NADAC-published product currently shares the active ingredient and strength of BUPRENORPHINE-NALOXONE 8-2 MG SL TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.

Who manufactures BUPRENORPHINE-NALOXONE 8-2 MG SL TABLET?

BUPRENORPHINE-NALOXONE 8-2 MG SL TABLET (NDC 16729055010) is labeled by Accord Healthcare Inc., and CMS classifies it as a generic product.